Xencor, Inc. (NASDAQ:XNCR) will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.xencor.com
Earnings Expectation
Xencor, Inc. is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.23 per share from revenue of $ 33.44 million. Looking ahead, the full year loss are expected at $ 1.57 per share on the revenues of $ 94.49 million.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The companys product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases.
